产品
编 号：F247573
分子式：C54H90N6O18
分子量：1111.32
分子式：C54H90N6O18
分子量：1111.32
产品类型
规格
价格
是否有货
1mg
280
In-stock
2mg
476
In-stock
5mg
920
In-stock
10mg
1520
In-stock
25mg
2736
In-stock
结构图
CAS No: 2001-95-8
产品详情
生物活性：
Valinomycin is a potassium-specific ionophore, the valinomycin-K+ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K+ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research.
体内研究：
Lipo-Valinomycin (1-40 μg/g, 静脉注射, 每二天, 16 d) 抑制裸鼠内的 HepG2 肿瘤生长。Animal Model:nude mice with HepG2
Dosage:1, 2, 5, 10, 20, 40 μg/g
Administration:Intravenous injection (i.v.), every two days for 16 d
Result:Exerted remarkable inhibition effect on tumor growth and no weight loss during the therapeutic period. Caused destructive tumor necrosis as most of the tumor cells were in apoptotic status.
体外研究：
Lipo-Valinomycin (1-100 μM, 24 h) 剂量依赖性地抑制 HepG2 的细胞活性。Lipo-Valinomycin (15 μM, 12 h) 破坏线粒体膜电位并诱导 HepG2 的细胞凋亡 (23%)。1.19Valinomycin 生物活性BioactivityTargetEfficacy
AntibacterialStreptococcus pyogenesMIC 0.02 μg/mL
Clostridium sporogenesMIC 8 μg/mL
Enterococcus faecalisMIC 0.39–0.78 μg/disk
Streptococcus pneumoniaeMIC 0.39–0.78 μg/disk
Micrococcus luteusMIC 25–50 μg/disk
AntifungalCandida albicansMIC 0.39–0.78 μg/disk
Cryptococcus neoformansMIC 50–100 μg/disk
Phytophthora capsiciIC50 15.9 μg/mL
Botrytis cinereaMIC 4 μg/mL
Magnaporthe griseaMIC 4 μg/mL
Candida albicansMIC 32 μg/mL
Colletotrichum gloeosporioidesMIC 256 μg/mL
Rhizoctonia solaniMIC 256 μg/mL
Penicillium verrucosumIC50 0.005 ng/mL
AntiviralSARS-CoVEC50 0.85 μM
PRRSVIC50 24 nM
RSVIC50 0.0015 μM
MERS-CoVIC50 84 nM
HCoV-OC43EC50 4.43 μM
HCoV-NL63EC50 1.89 μM
MHV-A59EC50 6.78 μM
LACVIC50 588 nM
RVFV MP-12IC50 41 nM
HRV2IC50 610 nM
CVB3IC50 971 nM
ZIKVIC50 78 nM
KEYVIC50 156 nM
HCoV-229EIC50 67 nM
LASVEC50 0.61 μM
LCMVEC50 0.15 μM
AntitumorHuman ovarian tumor cells CaOV-3IC50 0.1 nM
Murine P388 leukemia cancer cellsGI50 0.019 μg/mL
Human ovary OVCAR-3 tumor cellsGI50 0.19 ng/mL
Brain SF-295 tumor cellsGI50 0.35 ng/mL
Renal A-498 carcinoma cellsGI50 1.9 ng/mL
Lung NCI-H460 cancer cellsGI50 0.21 ng/mL
Colon KM20L2 carcinoma cellsGI50 0.27 ng/mL
Melanoma SK-MEL-5 cancer cellsGI50 0.26 ng/mL
Rat C6 glioma cellsIC50 0.4 μM
Human A2780 ovarian carcinoma cellsIC50 2.18 μM
Human MCF-7 breast carcinoma cellsIC50 1.77 μM
Human HepG2 hepatocellular carcinoma cellsIC50 0.0008 μM
Human U251 glioma cellsIC50 7.6 nM
Valinomycin is a potassium-specific ionophore, the valinomycin-K+ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K+ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research.
体内研究：
Lipo-Valinomycin (1-40 μg/g, 静脉注射, 每二天, 16 d) 抑制裸鼠内的 HepG2 肿瘤生长。Animal Model:nude mice with HepG2
Dosage:1, 2, 5, 10, 20, 40 μg/g
Administration:Intravenous injection (i.v.), every two days for 16 d
Result:Exerted remarkable inhibition effect on tumor growth and no weight loss during the therapeutic period. Caused destructive tumor necrosis as most of the tumor cells were in apoptotic status.
体外研究：
Lipo-Valinomycin (1-100 μM, 24 h) 剂量依赖性地抑制 HepG2 的细胞活性。Lipo-Valinomycin (15 μM, 12 h) 破坏线粒体膜电位并诱导 HepG2 的细胞凋亡 (23%)。1.19Valinomycin 生物活性BioactivityTargetEfficacy
AntibacterialStreptococcus pyogenesMIC 0.02 μg/mL
Clostridium sporogenesMIC 8 μg/mL
Enterococcus faecalisMIC 0.39–0.78 μg/disk
Streptococcus pneumoniaeMIC 0.39–0.78 μg/disk
Micrococcus luteusMIC 25–50 μg/disk
AntifungalCandida albicansMIC 0.39–0.78 μg/disk
Cryptococcus neoformansMIC 50–100 μg/disk
Phytophthora capsiciIC50 15.9 μg/mL
Botrytis cinereaMIC 4 μg/mL
Magnaporthe griseaMIC 4 μg/mL
Candida albicansMIC 32 μg/mL
Colletotrichum gloeosporioidesMIC 256 μg/mL
Rhizoctonia solaniMIC 256 μg/mL
Penicillium verrucosumIC50 0.005 ng/mL
AntiviralSARS-CoVEC50 0.85 μM
PRRSVIC50 24 nM
RSVIC50 0.0015 μM
MERS-CoVIC50 84 nM
HCoV-OC43EC50 4.43 μM
HCoV-NL63EC50 1.89 μM
MHV-A59EC50 6.78 μM
LACVIC50 588 nM
RVFV MP-12IC50 41 nM
HRV2IC50 610 nM
CVB3IC50 971 nM
ZIKVIC50 78 nM
KEYVIC50 156 nM
HCoV-229EIC50 67 nM
LASVEC50 0.61 μM
LCMVEC50 0.15 μM
AntitumorHuman ovarian tumor cells CaOV-3IC50 0.1 nM
Murine P388 leukemia cancer cellsGI50 0.019 μg/mL
Human ovary OVCAR-3 tumor cellsGI50 0.19 ng/mL
Brain SF-295 tumor cellsGI50 0.35 ng/mL
Renal A-498 carcinoma cellsGI50 1.9 ng/mL
Lung NCI-H460 cancer cellsGI50 0.21 ng/mL
Colon KM20L2 carcinoma cellsGI50 0.27 ng/mL
Melanoma SK-MEL-5 cancer cellsGI50 0.26 ng/mL
Rat C6 glioma cellsIC50 0.4 μM
Human A2780 ovarian carcinoma cellsIC50 2.18 μM
Human MCF-7 breast carcinoma cellsIC50 1.77 μM
Human HepG2 hepatocellular carcinoma cellsIC50 0.0008 μM
Human U251 glioma cellsIC50 7.6 nM
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备